| Q30431388 | A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies |
| Q43174266 | A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer |
| Q48666856 | A study on promoter methylation of PTEN in sporadic breast cancer patients from North India |
| Q100660457 | ARe we there yet? Understanding androgen receptor signaling in breast cancer |
| Q35853239 | ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells |
| Q36851633 | ATP modulates PTEN subcellular localization in multiple cancer cell lines. |
| Q51526882 | Abnormalities of proinsulin processing in functioning insulinomas: clinical implications. |
| Q35009571 | Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling |
| Q36677712 | Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. |
| Q36942597 | Analysis of PTEN expression in large intestine polyps and its relation to the recognized histopathological and clinical risk factors for cancer development in this location |
| Q39308117 | Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors |
| Q46598354 | Analysis of complex protein kinase B signalling pathways in human prostate cancer samples |
| Q37783931 | Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy |
| Q40624250 | Autocrine Signalling Through erbB Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines |
| Q44350476 | BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels |
| Q47250551 | BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer |
| Q35838511 | Bergapten drives autophagy through the up-regulation of PTEN expression in breast cancer cells |
| Q37168778 | Biomarkers of response to Akt inhibitor MK-2206 in breast cancer |
| Q74688995 | CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast |
| Q35101357 | Can we accurately report PTEN status in advanced colorectal cancer? |
| Q34479003 | Characteristics of triple-negative breast cancer |
| Q34079578 | Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line |
| Q36313163 | Class reunion: PTEN joins the nuclear crew. |
| Q35926060 | Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing |
| Q30278895 | Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma |
| Q37200911 | Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C. |
| Q35788734 | Considerations when analyzing the methylation status of PTEN tumor suppressor gene |
| Q34750104 | Contactin-1 reduces E-cadherin expression via activating AKT in lung cancer. |
| Q55431818 | Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis. |
| Q24796025 | Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice |
| Q37437827 | Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells |
| Q28117749 | Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis |
| Q35586140 | Diagnosis of premalignant endometrial disease |
| Q33895317 | Different conformations of phosphatase and tensin homolog, deleted on chromosome 10 (PTEN) protein within the nucleus and cytoplasm of neurons |
| Q87401555 | Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status |
| Q35810225 | Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors |
| Q39550412 | Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers |
| Q36827924 | Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1. |
| Q54373171 | EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. |
| Q39330537 | Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells |
| Q35640263 | Elevated PI3K signaling drives multiple breast cancer subtypes |
| Q37403650 | Enzymatic Analysis of PTEN Ubiquitylation by WWP2 and NEDD4-1 E3 Ligases |
| Q35745799 | Epigenetic PTEN silencing in malignant melanomas without PTEN mutation |
| Q46610505 | Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study. |
| Q46433342 | Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations |
| Q35559028 | Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity |
| Q38044974 | Everolimus in the treatment of hormone receptor-positive breast cancer |
| Q37205007 | Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases |
| Q40003836 | Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia. |
| Q79249861 | Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth |
| Q44599851 | Expression of PTEN in the progression of cervical neoplasia and its relation to tumor behavior and angiogenesis in invasive squamous cell carcinoma |
| Q54533454 | Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma. |
| Q37562651 | Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases |
| Q37383459 | Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression |
| Q35842249 | Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas |
| Q57591220 | Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas |
| Q46362755 | Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation |
| Q24679438 | Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility |
| Q34783505 | Genetic insights into familial cancers-- update and recent discoveries |
| Q33905657 | Germline Inactivation of PTEN and Dysregulation of the Phosphoinositol-3-Kinase/Akt Pathway Cause Human Lhermitte-Duclos Disease in Adults |
| Q37380558 | Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest |
| Q80629440 | Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families |
| Q33944717 | Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression |
| Q73410694 | Heterogeneous lack of expression of the tumour suppressor PTEN protein in human neoplastic tissues |
| Q51721747 | High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer. |
| Q36236071 | Hormonal influences on cancer progression and prognosis |
| Q45222465 | Hypoglycemia in response to glucose and glucagon in insulinoma patients with a negative prolonged fast: functional and morphological properties |
| Q38980829 | Identification of nucleolus-localized PTEN and its function in regulating ribosome biogenesis |
| Q91669799 | If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease |
| Q38308779 | Immunohistochemical assessment of PTEN in vulvar cancer: best practices for tissue staining, evaluation, and clinical association. |
| Q42519161 | Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). |
| Q46467683 | Immunohistochemical profiles of brain metastases from breast cancer |
| Q46386017 | Increased activated Akt expression in renal cell carcinomas and prognosis |
| Q90448698 | Infantile macrocephaly and multiple subcutaneous lipomas diagnosed with PTEN hamartoma tumor syndrome: A case report |
| Q40368388 | Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival |
| Q36870653 | Insulin-like growth factor binding proteins and breast cancer |
| Q36092726 | Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer |
| Q89622441 | Integrative Transcriptomic Analysis Reveals a Multiphasic Epithelial-Mesenchymal Spectrum in Cancer and Non-tumorigenic Cells |
| Q37813694 | Intrinsic resistance to chemotherapy in breast cancer |
| Q37351203 | Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms |
| Q40606247 | Kinase-dead PKB gene therapy combined with hyperthermia for human breast cancer |
| Q49301755 | Knockdown of Phospholipase Cε (PLCε) Inhibits Cell Proliferation via Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)/AKT Signaling Pathway in Human Prostate Cancer |
| Q74054452 | Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma |
| Q42441080 | Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors |
| Q24653934 | Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer |
| Q43675669 | Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer |
| Q79327416 | Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression |
| Q89641392 | Loss of phosphatase activity in PTEN (phosphatase and tensin homolog deleted on chromosome ten) results in endometrial carcinoma in humans: An in-silico study |
| Q35151381 | Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN. |
| Q40169158 | Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity |
| Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
| Q93048684 | MiRNAs Are Involved in Tall Cell Morphology in Papillary Thyroid Carcinoma |
| Q35745875 | Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells |
| Q24806542 | New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists |
| Q42218359 | Nongenomic Mechanisms of PTEN Regulation |
| Q57591227 | Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma |
| Q34616536 | PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells |
| Q64235738 | PTEN Genetic and Epigenetic Alterations Define Distinct Subgroups in North Indian Breast Cancer Patients |
| Q27824857 | PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer |
| Q38629644 | PTEN and PI3K/AKT in non-small-cell lung cancer. |
| Q34193836 | PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck |
| Q37254063 | PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis |
| Q24801835 | PTEN deficiency: a role in mammary carcinogenesis |
| Q74141759 | PTEN expression is maintained in sporadic colorectal tumours |
| Q24528114 | PTEN function: how normal cells control it and tumour cells lose it |
| Q44702044 | PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus |
| Q37139779 | PTEN in brain tumors |
| Q36361389 | PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome. |
| Q40639993 | PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatase activity of PTEN downregulates IGF-II expression in hepatoma cells |
| Q53300858 | PTEN mutation spectrum in breast cancers and breast hyperplasia. |
| Q37092758 | PTEN mutation, methylation and expression in breast cancer patients |
| Q35747653 | PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers |
| Q57591147 | PTEN mutations are common in sporadic microsatellite stable colorectal cancer |
| Q34796595 | PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium |
| Q82600359 | PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas |
| Q50977901 | PTEN, Longevity and Age-Related Diseases. |
| Q27851582 | PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. |
| Q34540849 | PTEN: The down side of PI 3-kinase signalling. |
| Q38406254 | PTEN: a yin-yang master regulator protein in health and disease |
| Q28203387 | PTEN: one gene, many syndromes |
| Q42921293 | PTENtumor suppressor plays less prognostic role thanP53tumor suppressor in diffuse large B-cell lymphoma |
| Q47989087 | Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute |
| Q35870069 | Partial PTEN deletion is linked to poor prognosis in breast cancer |
| Q24801684 | Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? |
| Q37817187 | Phosphoproteomics: A possible route to novel biomarkers of breast cancer |
| Q35757521 | Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. |
| Q37270440 | Post-translational regulation of PTEN. |
| Q33359798 | Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study |
| Q64114534 | Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology |
| Q36277982 | Progesterone regulates the proliferation of breast cancer cells - in vitro evidence |
| Q80403566 | Promoter methylation of the PTEN gene is a common molecular change in breast cancer |
| Q34048140 | Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer |
| Q34066409 | Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma |
| Q42125233 | Pten, a protean tumor suppressor |
| Q36643707 | Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. |
| Q45099758 | Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen |
| Q47834443 | Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors |
| Q36950684 | Regression of latent endometrial precancers by progestin infiltrated intrauterine device |
| Q47393112 | Regulation of Signal Transduction by DJ-1. |
| Q36727409 | Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression |
| Q46859745 | Role of the PI3K/Akt, mTOR, and STK11/LKB1 pathways in the tumorigenesis of sclerosing hemangioma of the lung |
| Q36934463 | SGK3 is associated with estrogen receptor expression in breast cancer |
| Q38969138 | Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways |
| Q39845007 | Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration |
| Q36771848 | Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway |
| Q41469992 | Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients |
| Q34565498 | Steroid hormone mimics: molecular mechanisms of cell growth and apoptosis in normal and malignant mammary epithelial cells |
| Q33905794 | Suppression of cell migration by phospholipase C-related catalytically inactive protein-dependent modulation of PI3K signalling |
| Q43227938 | Synchronous bilateral breast carcinoma in a patient with cowden syndrome: a case report with morphologic, immunohistochemical and genetic analysis |
| Q34096222 | Targeted Therapy in Metastatic Breast Cancer: The HER2/neu Oncogene |
| Q35372584 | Targeted therapies for breast cancer |
| Q48112143 | Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy |
| Q35584560 | Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer |
| Q64250687 | The Antioxidant from Ethanolic Extract of Fruits Activates Phosphatase and Tensin Homolog In Vitro and In Vivo: A New Insight on Its Antileukemic Effect |
| Q37261822 | The association of PTEN hypermethylation and breast cancer: a meta-analysis |
| Q36312142 | The impact of PTEN tumor suppressor gene on acquiring resistance to tamoxifen treatment in breast cancer patients |
| Q36561728 | The mTOR pathway in breast cancer |
| Q37797943 | The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer |
| Q33274011 | The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target |
| Q40420028 | The soy isoflavone genistein promotes apoptosis in mammary epithelial cells by inducing the tumor suppressor PTEN. |
| Q24290417 | The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation |
| Q54331857 | Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. |
| Q48030104 | Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients |
| Q57741132 | Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors |
| Q37270444 | Understanding PTEN regulation: PIP2, polarity and protein stability |
| Q33984914 | Upregulated DJ-1 promotes renal tubular EMT by suppressing cytoplasmic PTEN expression and Akt activation |
| Q36442445 | Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes |
| Q35889659 | Variants on the promoter region of PTEN affect breast cancer progression and patient survival |
| Q37863123 | mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy |
| Q36424194 | microRNA-21 overexpression contributes to cell proliferation by targeting PTEN in endometrioid endometrial cancer |